Feasibility and performance of the Idylla™ NRAS/BRAF cartridge mutation assay on thyroid liquid-based fine-needle aspiration.

Maud HamadouJonathan LopezNazim BenzerdjebChristine Cugnet-AnceauGwenaelle SchnoeringJulie BesançonSaliha MezragVeronique LaprasMarie-Laure DenierFrançoise DescotesMyriam Decaussin-Petrucci

Published in: Diagnostic cytopathology (2021)

Idylla™ NRAS/BRAF mutation testing can be performed on residual thyroid LB-FNA, using low DNA quantity input, thus not requiring a dedicated sample. The Idylla™ NRAS/BRAF assay offers a quick and easy first step for analyzing the main molecular alterations in indeterminate thyroid nodules, hence improving diagnostic management.

Keyphrases

wild type
fine needle aspiration
ultrasound guided
high throughput
metastatic colorectal cancer
single molecule
circulating tumor
cell free
ionic liquid